Citations

Clear

4610 citation(s) found for "Lu, Brian".

Acute Valve Syndrome Before Aortic Valve Replacement: Impact on Clinical Outcomes, Health Care Costs, and Resource Use
Généreux, Philippe , Lindman, Brian R. , Pîbarot, Philippe , Baron, Suzanne J. , Asselin, Chantal , Dratch, Alissa , Murphy, Shannon , Chikermane, Soumya , Thourani, Vinod H. , Koulogiannis, Konstantinos , Schwartz, Allan , Leon, Martin B. , Gillam, Linda D. , Lindman, Brian R , Pibarot, Phillippe , Baron, Suzanne J , Asselin, Chantal , Dratch, Alissa , Murphy, Shannon M E , Chikermane, Soumya , Koulogiannis, Kostantinos P , Schwartz, Allan , Leon, Martin B. , Pellikka, Patricia A , Gillam, Linda D , Généreux, Philippe , Giustino, Gennaro , Pellikka, Patricia A.

Mayo Clinic

Journal of the American Heart Association | September 30, 2025 | Volume: 14 | Issue: 19 | Pages: No page available

10.1161/jaha.125.043486 | PMID 41025452 Get It

Background A classification system describing clinical presentation before aortic valve replacement (AVR) has recently been proposed (stable valve syndrome [SVS]), mildly symptomatic (progressive valve syndrome), or with acute and severe signs and symptoms (acute valve syndrome [AVS]). We aimed to evaluate the clinical impact, health care costs, and resource use associated with the mode of clinical presentation at the time of AVR among patients presenting with aortic stenosis. Methods Using the Market Clarity database (2017–2023), patients >18 years old with aortic stenosis and undergoing AVR (transcatheter or surgical) were included. Patients were categorized as SVS, progressive valve syndrome, or AVS based on their clinical presentation during the 1 year before AVR. All‐cause death, heart failure hospitalization, total health care costs (index hospitalization plus 1‐year follow‐up), and resource use were compared across clinical presentation groups using adjusted regression models. Results Of the 24 075 patients undergoing AVR for aortic stenosis, 270 (1.1%) had SVS, 10 195 (42.3%) progressive valve syndrome, and 13 610 (56.5%) AVS. Compared with SVS, AVS presentation was associated with increased risk of 1‐year death (adjusted hazard ratio [aHR], 2.93 [95% CI, 1.1–7.8]; P =0.03) and heart failure hospitalization (aHR, 4.15 [95% CI, 1.6–11.1]; P <0.01) after AVR. The total costs of AVR and 1‐year follow‐up were significantly higher in both the progressive valve syndrome (difference $27 410 [$13 507–$41 314]) and AVS groups (difference $36 267 [$22 302–$50 232]) compared with patients with SVS. Conclusions AVS was frequent among patients undergoing AVR and was associated with increase in death, heart failure hospitalization, health care costs, and resource use 1 year after AVR, and SVS presentation was associated with the best clinical and economic outcomes.
Primary Care Clinician Preferences and Perspectives on Multi-Cancer Detection Testing Across an Integrated Healthcare System
Austin, Jessica D. , Nelson, Ilyse A., Tilburt, Jon C. , Ellinghysen, Eric R., Yee, Claire , Quillen, Jaxon , Dougan, Brian M. , Presutti, John R., Samadder, N. Jewel , Ghosh, Karthik, Ressler, Steven W. , Hurt, Ryan T. , Samadder, Niloy Jewel, Ressler, Steven W , Ghosh, Karthik , Austin, Jessica D , Yee, Claire , Quillen, Jaxon K , Nelson, Ilyse A.

Mayo Clinic

Journal of Personalized Medicine | September 29, 2025 | Volume: 15 | Issue: 10 | Pages: 452

10.3390/jpm15100452 | PMID 41149814 Get It

Background/Objectives: Multi-cancer detection (MCD) tests have emerged as a promising tool to redefine the landscape of early cancer detection. Implementation of this novel technology will likely fall to primary care clinicians (PCC). The purpose of this study is to characterize and explore differences in PCCs perceptions and preferences towards MCD testing. Methods: Between March and May of 2023, this cross-sectional survey was administered to 281 PCCs, including physicians and advanced care providers practicing within an integrated healthcare system spanning five states. The survey collected data on self-reported characteristics, perceptions of MCD testing, and preferences for learning about MCD testing. Analysis was limited to those with no prior experience with MCD testing (N = 181, response rate 22.8%). Descriptive statistics summarized key variables and chi-square tests assessed differences in perceptions and preferences by key characteristics. Results: Most PCCs were interested in MCD testing (66.3%), but limited knowledge/awareness of MCD testing and confidence to manage patients with a positive test were observed, along with concerns around cost (76.7%) and misuse/poor implementation. The primary preferences for learning about MCD testing were online courses or classroom instruction (64.5%). Significant differences in perceptions and preferences for learning were observed by location, degree, and years in practice. Conclusions: PCCs in our study held positive views towards MCD testing, but gaps and variation in knowledge and confidence towards MCD testing and concerns around the cost and misuse/poor implementation were observed. While efforts to train and educate all PCCs on MCD testing is a critical first step, more research is needed to understand how best to support implementation tailored to individual and system-level needs and characteristics.
Abstract B070: Pancreatic Cancer Detection Consortium biomarker bake-off: A consortium Phase 2 blinded biomarker validation and panel discovery study
Oberg, Ann L. , Izmirlian, Grant , Balasenthil, Seetharaman , Herman, Daniel S. , Killary, Ann M. , Natarajan, Gopalakrishnan, Sen, Subrata , Srivastava, Sudhir , Wolpin, Brian M. , Zaret, Kenneth S. , Bamlet, William R. , Batra, Surinder K. , Hayashi, Masataka , Hollingsworth, Michael A. , Jain, Maneesh , Krusen, Brianna M. , Liu, Suyu , Natarajan, Gopalakrishnan, Smith, Lynette M. , Goggins, Michael

Mayo Clinic

Cancer Research | September 28, 2025 | Volume: 85 | Issue: 18_Supplement_3 | Pages: B070-B070

10.1158/1538-7445.pancreatic25-b070 Get It

Abstract Objective: The Pancreatic Cancer Detection Consortium (PCDC) performed a blinded EDRN defined phase 2 Biomarker Bakeoff study of eight promising biomarker panels using pancreatic cancer ductal adenocarcinoma (PDAC) case and general population healthy control samples from three institutions. The scientific questions were to determine whether panels could discriminate PDAC cases from controls with Receiver Operating Characteristic Area Under the Curve (AUC) &gt; 0.8, compare panel performance head-to-head via 95% confidence intervals (CI), and determine whether the panel improved upon serum CA19-9 alone. A secondary goal was to perform modeling to discover a new panel consisting of individual biomarkers. Methods: Eligible biomarkers were required to have had a prior EDRN defined phase 2 validation study published and be ready for validation in a sample set from multiple institutions. Three institutions submitted a total of 140 cases and 140 controls frequency matched to cases on age and sex. Four consortium member institutions submitted for validation eight panels consisting of ten plasma, serum and DNA genotyping biomarkers in addition to CA19-9. Locked panel formulas were submitted prior to specimen distribution. The primary metric was AUC with bootstrapped 95% CIs. LASSO penalized regression was used for exploratory panel building. Nested cross validation and internal-external validation were performed, and optimism-corrected performance estimates were computed. Results: The overall sample (N=280) was 51% female, median age of 67 years, and 94% were of non-Hispanic white race and ethnicity. Controls had median BMI 27.3, 56% never smokers, and 12% type II diabetes mellitus (DM2); cases (staged I to IV) had median BMI 26.6, 42% never smokers, and 26% DM2. Overall panel AUC estimates ranged from 89.9 to 96.3 and all were significantly larger than the null hypothesis value of 0.8 (p&lt;0.05). The apparent serum CA19-9 AUC was 91.7 (87.8, 95.6). Two panels were significantly different from serum CA19-9, a panel with FUT2/3 genotype with serum CA19-9 (p=0.002) and a panel containing tissue factor pathway inhibitor (TFPI), tenascin C (TNC), and plasma CA19-9 (p=0.01). In subset analyses by PDAC stage, no panel improved upon the null hypothesis value of 0.8 in stage I (p&gt;0.05), all panels improved upon the null hypothesis value of 0.8 in stage II and III (p&lt;0.05), and only serum CA19-9 did not improve upon the null hypothesis value of 0.8 in stage IV. All biomarkers but two microRNAs were retained in a LASSO model that had optimism corrected AUC=96.4 (95% CI: 94.0, 98.9). Conclusions: All submitted panels performed well overall in this blinded study, with the panel containing FUT2/3 genotype performing the best. Panel discovery improved upon serum CA19-9, though optimism corrected AUC 95% CIs overlap with those of apparent CA19-9 performance. Further work is needed to prioritize promising biomarkers and to improve detection of early stage PDAC. Citation Format: Ann L. Oberg, William R. Bamlet, Grant Izmirlian, Seetharaman Balasenthil, Surinder K. Batra, Masataka Hayashi, Daniel Herman, Michael A. Hollingsworth, Maneesh Jain, Ann M. Killary, Brianna M. Krusen, Suyu Liu, Gopalakrishnan Natarajan, Subrata Sen, Lynette M. Smith, Sudhir Srivastava, Brian M. Wolpin, Kenneth S. Zaret, Michael G. Goggins. Pancreatic Cancer Detection Consortium biomarker bake-off: A consortium Phase 2 blinded biomarker validation and panel discovery study [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research—Emerging Science Driving Transformative Solutions; Boston, MA; 2025 Sep 28-Oct 1; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2025;85(18_Suppl_3):Abstract nr B070.
Intracranial Occlusion in Cryptogenic Stroke Is Not Predictive of Recurrent Ischemic Stroke: A Propensity‐Score Matched Analysis of the Cardiac Abnormalities in Stroke Prevention and Risk of Recurrence Study
Brorson, James R. , Badillo‐Goicoechea, Elena , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M. , Khasiyev, Farid , Kerrigan, Deborah , Lewis, Skylar, Ali, Hamid , Melkumova, Emiliya , Dumitrascu, Oana M. , Parikh, Parth , Doolittle, Charles, Yahnke, Ian, Sathya, Anvitha , Brown, Samantha , Kang, Jieun, Bowman, Anna, Shahrivari, Mahan, Sehgal, S , Alvi, Muhammad , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Qdais, Ahmad Abu, Quintela, Gustavo Antezana, Sharma, Richa, Thottempudi, Neeharika, Nedelcu, Simona , Herpich, Franziska , Glover, Patrick , Chahien, Dalia, Liebeskind, David S. , Linares, Guillermo , Daniel, Jean‐Philippe, Kasab, Sami Al , Singh, Eesha , D’Souza, Maria , Gaudio, Elizabeth, Kala, Narendra , Sarkar, Monica , Coevering, Russell J. Van , Thon, Jesse , Thompson, Sean, Lineback, Christina , Brorson, James R , Penckofer, Mary , Eklund, Kelsey , Stretz, Christoph , Lineback, Christina M , Khasiyev, Farid , Kerrigan, Deborah , Ali, Hamid , Aboul-Nour, Hassan , de Havenon, Adam H , Culbertson, Collin J , Melkumova, Emiliya , Jillella, Dinesh V , Dumitrascu, Oana M , Parikh, Parth , Sathya, Anvitha , Brown, Samantha J , Elangovan, Cheran , Sehgal, Siddharth , Sloane, Kelly L , Krishnaiah, Balaji , Kam, Wayneho , Kothari, Sachin , Farooqui, Mudassir , Nahab, Fadi B , Sharma, Richa , Nedelcu, Simona , Herpich, Franziska , Liebeskind, David S. , Linares, Guillermo , Al Kasab, Sami , Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric D , Van Coevering, Russell J , Thon, Jesse , Stamm, Brian , Siegler, James E , Lineback, Christina M , Daniel, Jean-Philippe Auguste , Smith, Matthew M. , Nour, Hassan Aboul , Havenon, Adam de , Jillella, Dinesh , Doolittle, Charles, Elangovan, Cheran , Sharma, Richa , Thottempudi, Neeharika , D'Souza, Marissa, Aziz, Yasmin , Yaghi, Shadi , Goldstein, Eric , Chen, Lucia , Stamm, Brian , Siegler, James E.

Mayo Clinic

Journal of the American Heart Association | September 25, 2025 | Volume: 14 | Issue: 19 | Pages: No page available

10.1161/jaha.125.041500 | PMID 40996035 Get It

Background Intracranial occlusions in embolic stroke of undetermined source are histopathologically similar to cardiac sources of embolism. Whether patients with embolic stroke of undetermined source and intracranial occlusion benefit from anticoagulation is unknown. Methods A multicenter retrospective cohort of adults with cryptogenic stroke was queried for patients with proximal or medium/distal vessel occlusion. The primary outcome was recurrent ischemic stroke, which was assessed in unadjusted and adjusted Cox proportional hazards models and repeated following 1:1 propensity score matching and biweight kernel density matching. Results Of the 2328 patients who were followed over a median of 1.31 years (interquartile range, 0.34–2.85), 999 (42.6%) had an intracranial occlusion. When compared with patients without an intracranial occlusion, those with an occlusion had fewer atherosclerotic vascular risk factors, more severe symptoms, and less severe cerebral microvascular disease. The rate of recurrent stroke was similar between patients with versus without an intracranial occlusion (6.8%/year [95% CI, 5.7–8.2] versus 7.0%/year [95% CI 6.0–8.1]; adjusted hazard ratio [HR], 1.09 [95% CI, 0.77–1.55]). There was no association between occlusion and recurrent stroke in the adjusted propensity score matching (HR, 1.01 [95% CI, 0.64–1.59]) or kernel density models (HR, 0.95 [95% CI, 0.62–1.45]). There was no interaction between occlusion and treatment with anticoagulation, sex, age, or high‐risk sources of embolism for the primary outcome in the unmatched and matched analyses. Conclusions Intracranial occlusion in patients with embolic stroke of undetermined source is not associated with a greater risk of recurrence when compared with patients without an intracranial occlusion. There was no difference in rate of recurrent stroke with anticoagulation when stratified by presence or absence of occlusion.
Abstract B027: iSIGN panel identifies germ cell tumors via whole-proteome phage immunoprecipitation sequencing
Hammami, M Bakri , Costello, Brian A. , Lorenzo, Silvana De, Leibovich, Bradley C. , Cheville, John C. , Sagen, Jessica, Algeciras-Schimnich, Alicia, Pittock, Sean J, Mills, John R. , Dasari, Surendra , Bakri, Hammami M , Knight, Andrew, Kherbek, Haidara , Guo, Yong , Olson, Janet E. , Algeciras‐Schimnich, Alicia , Pittock, Sean J. , Dubey, Divyanshu

Mayo Clinic

Cancer Immunology Research | September 24, 2025 | Volume: 13 | Issue: 9_Supplement | Pages: B027-B027

10.1158/2326-6074.cimm25-b027 Get It

Abstract Purpose: Germ cell tumors (GCTs) pose significant diagnostic challenges due to the limited sensitivity and specificity of current tumor markers. Hereby we utilize phage immunoprecipitation sequencing (PhIP-Seq) technique to develop a unique immunosignature panel (iSIGN) with high sensitivity and specificity to improve the diagnosis and differentiation of GCTs. Patients and Methods: Serum samples from patients with confirmed gonadal or extragonadal GCTs and controls were collected from Mayo Clinic repositories. Controls included benign testicular lesions, autoimmune diseases, neurodegenerative disorders, and other cancers. Samples were randomized into development and validation cohorts. PhIP-Seq identified antigen-autoantibody interactions, and enrichment scores were calculated to develop a biomarker panel distinguishing GCT from non-GCT cases. A second biomarker panel was developed to predict seminoma from nonseminoma cases. Results: A total of 427 serum samples were analyzed, including 150 from GCT patients and 277 controls. For our primary model to distinguish GCT cases (GCT-iSIGN), 24 peptides from 16 antigens were identified based on significant differential autoantibody binding enrichment in GCT patients (p &lt; 0.05), ≥2 peptides per antigen, and enrichment scores ≥ 2.5-fold. GCT-iSIGN was highly sensitive (93%) and specific (99%) for identifying GCT cases from controls with an area under curve (AUC) of 0.93 and 9% Unknown Case Rate (UCR). The secondary panel (Sem-iSIGN) included 17 peptides corresponding to 5 unique proteins with high specificity (93%), moderate sensitivity (65%) and AUC of 0.77 to distinguish seminoma from nonseminoma GCT cases. Conclusion: This study demonstrates the potential use of PhIP-Seq to identify unique immunosignature panels that can serve as reliable biomarkers for GCT. These panels address the limitations of traditional markers and other proteomic techniques. This immunosignature model represents a cost-effective, stable, and scalable approach to enhancing GCT diagnosis and management. Citation Format: M Bakri Hammami, Andrew Knight, Haidara Kherbek, Brian Costello, Silvana De Lorenzo, Bradley C. Leibovich, John C. Cheville, Yong Guo, Jessica Sagen, Janet E. Olson, Alicia Algeciras-Schimnich, Sean J. Pittock, John R. Mills, Surendra Dasari, Divyanshu Dubey. iSIGN panel identifies germ cell tumors via whole-proteome phage immunoprecipitation sequencing [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity; 2025 Sep 24-27; Montreal, QC, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(9 Suppl):Abstract nr B027.
Greater large conducting airway luminal area in adult patients with interstitial lung disease
Miller, Alex J. , Ovrom, Erik A. , Zaremba, Solomiia , Senefeld, Jonathon W. , Wiggins, Chad C. , Dominelli, Paolo B. , Ripoll, Juan G. , Welch, Brian T. , Ramsook, Andrew H. , Joyner, Michael J , Ramsook, Andrew H , Wiggins, Chad C , Senefeld, Jonathon W , Zaremba, Solomiia , Joyner, Michael J.

Mayo Clinic

Physiological Reports | September 24, 2025 | Volume: 13 | Issue: 18 | Pages: No page available

10.14814/phy2.70578 | PMID 40991235 Get It

AbstractInterstitial lung disease (ILD) encompasses pulmonary disorders characterized by chronic inflammation and fibrosis that disrupt pulmonary gas exchange. While ILD‐related changes in the lung parenchyma are well‐documented, less is known about how ILD affects luminal area within the large conducting airways. This retrospective, case–control study tested the hypothesis that patients with ILD would have greater large conducting airway luminal areas than healthy matched controls. Three‐dimensional reconstructions of computed tomography images were used to quantify airway luminal areas in patients with ILD (n = 82; 54% female) and healthy controls matched for age, sex, and height. Patients with ILD had 16%–22% greater airway luminal areas across all seven measured large conducting airways compared to controls (all p < 0.001). Among patients with ILD, males had 17%–34% greater height‐normalized airway luminal areas than females (all p < 0.05). These data provide evidence that ILD is associated with greater large conducting airway luminal area, even when matched for key demographic factors. Consistent with observations in health, males with ILD exhibited greater height‐normalized airway size than females. These findings offer new insight into airway remodeling in ILD and highlight potential sex differences in airway luminal area.
The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology
McDade, Eric , Barthélemy, Nicolas R. , Wang, Guoqiao , Li, Yan , Cao, Yuchen , Clifford, David B., Goate, Alison , Renton, Alan E., Hassenstab, Jason , Perrin, Richard J. , Xiong, Chengjie , Mummery, Catherine J. , Berman, Sarah , Roberson, Erik D. , Dyck, Christopher van , Gauthier, Serge , Masters, Colin L. , Bittner, Tobias , Yaari, R. , Chhatwal, Jasmeer P. , Chrem, Patricio, Xiong, Chengjie , Ringman, John M. , Ryan, Natalie S. , Day, Gregory S. , Daniels, Alisha , Morris, John C., Supnet, Charlene , Team, The DIAN‐TU Study Team and DIAN Obs, McDade, Eric M , Bateman, Randall J , Roberson, Erik , Day, Gregory S , Masters, Colin L , Xiong, Chengjie , Hassenstab, Jason , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Gordon, Brian A. , Benzinger, Tammie L.S. , Renton, Alan , Llibre‐Guerra, Jorge J. , Xiong, Chengjie , Cruchaga, Carlos , Lah, James J. , Masellis, Mario , Brooks, William S. , Suzuki, Kazushi , Jucker, Mathias , Wallon, David , Ikeuchi, Takeshi , Lee, Jae‐Hong , Roh, Jee Hoon , Schofield, Peter R. , Fox, Nick C. , Vöglein, Jonathan , Karch, Celeste M. , Ibanez, Laura , Sánchez‐Valle, Raquel , Morris, John C. , Levey, Allan I. , Bateman, Randall J. , Team, The DIAN‐TU Study Team and DIAN Obs

Mayo Clinic

Alzheimer's & Dementia | September 23, 2025 | Volume: 21 | Issue: 9 | Pages: No page available

10.1002/alz.70689 | PMID 40985290 Get It

Abstract BACKGROUND Tau‐derived cerebrospinal fluid (CSF) biomarkers correlate with amyloid‐beta (Aβ) plaques or tau tangles in Alzheimer's disease (AD). This study assessed the effects of long‐term anti‐Aβ antibodies on amyloid plaques, tau tangles, and CSF tau species to determine the relationships between them. METHODS A post‐hoc analysis of the DIAN‐TU‐001 trial (NCT01760005) examined 142 participants at risk for dominantly inherited AD randomized to solanezumab ( n = 50), gantenerumab ( n = 52), or placebo ( n = 40). High‐resolution mass spectrometry quantified CSF tau species over four years. RESULTS Phosphorylated tau (p‐tau) species (153, 181, 217, 231) increased early in preclinical AD but were reduced with gantenerumab‐mediated Aβ plaque reduction. Nearly a decade later, MTBR‐tau243 and p‐tau205 increased, showing no association with Aβ reduction, aligning with tau tangle pathology progression. DISCUSSION Initially changing soluble p‐tau species track Aβ plaque reduction, while ptau205 and MTBR‐243 reflect tau tangle pathology, informing different pathways of therapeutic strategies. Highlights p‐tau217 and p‐tau231 correlate with Aβ‐PET and respond to Aβ‐plaque lowering therapies. Aβ immunotherapy trials support a direct link between p‐tau changes and Aβ plaques Gantenerumab reduces Aβ plaques but does not affect tau NFT‐related biomarkers. Blood‐based p‐tau217 assays may provide a non‐invasive tool to monitor Aβ therapies. MTBR‐tau243 strongly correlates with tau PET and tracks NFT pathology progression. Further studies are needed to validate tau biomarkers for tracking NFT‐targeting therapies.
Community-based participatory design of a decade: the FAITH! Cardiovascular Health and Wellness Program
Lalika, Mathias , Kyalwazi, Ashley, Albertie, Monica, Bowie, Janice , Burgess, Ashya, Elegbede, Walé, Erickson, Jamia, Jenkins, Sarah M. , Johnson, Jacquelyn, Krogman, Ashton , Moen, Lainey , Palmer, Michael W. , Penheiter, Sumedha G., Richard, Monisha, Titus, Princess, Schardin, Sueling, Shanedling, Stanton , Hof, Jeremy Van’t , Weis, Jennifer A., Patten, Christi A. , Penheiter, Sumedha, Warner, David, Weis, Jennifer, Brewer, LaPrincess C. , Burke, Lora E. , Buta, Brian J. , Cooper, Lisa A. , Crews, Deidra C. , Doubeni, Chyke A. , Johnson, Jacquelyn, Jones, Clarence , Palmer, Michael, Warner, David O. , Hayes, Sharonne N.

Mayo Clinic

Frontiers in Public Health | September 23, 2025 | Volume: 13 | Issue: No issue available | Pages: No page available

10.3389/fpubh.2025.1622237 | PMID 41063935 Get It

The FAITH! (Fostering African-American Improvement in Total Health) Cardiovascular Health and Wellness Program is more than a decade-long community-based participatory research initiative aimed at addressing cardiovascular health disparities among African-Americans in Minnesota. Founded in 2013, the program employs a culturally tailored, community-driven approach by partnering with African-American faith communities to promote cardiovascular health through education, digital health tools, and multilevel interventions targeting the social determinants of health. Grounded in community-based participatory research principles, FAITH! prioritizes equitable academic-community partnerships, co-learning, community capacity building, and shared ownership in all aspects of research and implementation. The program’s exemplary innovations include the NIH-funded FAITH! Trial, a randomized clinical trial, testing a mobile health intervention (the FAITH! App) co-created with the African-American community, and the Techquity by FAITH! study. Techquity by FAITH! evaluates the effectiveness of a culturally relevant, community-informed mHealth intervention supported by a Digital Health Advocate network to improve overall cardiovascular health and digital health literacy. During its evolution, FAITH! has addressed emergent public health crises, including the COVID-19 pandemic, by adapting programming to provide emergency preparedness resources, health education, and vaccine outreach. Key outcomes include sustainable church-based health ministries, increased research participation, and successful translation of research into practice. The program has also contributed to research workforce development by mentoring and training diverse early-career scholars and community leaders in community-based participatory research and cardiovascular health equity research. Lessons learned highlight the transformative impact of community-based participatory research in building trust, facilitating culturally relevant dissemination, and sustaining health equity initiatives. The FAITH! model demonstrates a scalable, community-led strategy for advancing cardiovascular health in underserved populations and provides a blueprint for future initiatives aiming to reduce racial health disparities.
Cross‐Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease
Abdelmoity, Omar , Wisch, Julie K. , Kennedy, James T. , Vlassenko, Andrei G. , Handen, Benjamin L. , Head, Elizabeth , Lai, Florence , Rosas, H. Diana , Hartley, Sigan L. , Tudorascu, Dana , Keefe, Sarah , Ikeuchi, Takeshi, Morris, John C., Roh, Jee Hoon , Day, Gregory S. , Xiong, Chengjie , Head, Elizabeth , Lao, Patrick , Keefe, Sarah , Roh, Jee Hoon , Day, Gregory S , Gordon, Brian A , Xiong, Chengjie , Wisch, Julie K , Goyal, Manu S. , Flores, Shaney , Keator, David B. , Rafii, Michael S. , Zaman, Shahid H. , Brickman, Adam M. , Lee, Joseph H. , Allegri, Ricardo , Fougère, Christian la , Llibre‐Guerra, Jorge J. , Ikeuchi, Takeshi , Morris, John C. , Schofield, Peter R. , Gordon, Brian A. , Benzinger, Tammie L.S. , Ances, Beau M.

Mayo Clinic

Annals of Neurology | September 22, 2025 | Volume: 98 | Issue: 6 | Pages: 1237-1248

10.1002/ana.78002 | PMID 40977577 Get It

Objectives Directly compare the brain glucose patterns seen with [F‐18] fluorodeoxyglucose (FDG) positron emission tomography (PET) between 2 genetically determined forms of Alzheimer's disease: Down syndrome (DS) and autosomal dominant Alzheimer's disease (ADAD). Methods Cross‐sectional analyses of FDG were performed in individuals with DS (n = 76) from the Alzheimer Biomarker Consortium‐Down Syndrome (ABC‐DS), ADAD (n = 297), and neurotypical familial controls (n = 188) from the Dominantly Inherited Alzheimer Network (DIAN). Within‐group linear regression models and generalized additive models were performed for select regional FDG uptake measures (isthmus cingulate and inferior parietal, precuneus, middle temporal gyrus, and precentral gyrus). Age, sex, apolipoprotein (APOE) ε4 carrier status, and cortical amyloid burden were included within these analyses. Results Even 20 years before expected onset of clinical symptoms, FDG uptake was lower for DS compared to neurotypical familial controls ( p < 0.01). ADAD baseline FDG was similar to neurotypical familial controls until 7 years before expected symptom onset. Both symptomatic individuals with DS and ADAD had lower FDG compared to neurotypical familial controls ( p < 0.01). A higher amyloid burden was associated with lower FDG for both genetic forms, with similar rates of decline in FDG uptake for DS and ADAD who were amyloid positive. Interpretation Brain glucose metabolism is substantially lower for people with DS, even in individuals who are cognitively stable. The patterns of FDG decline are distinct in these 2 genetically determined forms of AD. The diagnostic utility of FDG‐PET is specific to the genetic form of AD. ANN NEUROL 2025;98:1237–1248
Supporting cancer research on real-world data: extracting colorectal cancer status and explicitly written TNM stages from free-text imaging and histopathology reports
Tamm, Andres , Jones, Helen , Doshi, Neel , Perry, William , Withers, Joshua, Salih, Hizni , Noble, Theresa , Little, Stephanie , Roadknight, Gail , Campell, D.J., Matharu, Sheila, Teare, Marion, Galdikas, A., Papadimitriou, Dimitri , Scanlon, Lauren , Woods, Kerrie , Cunningham, Chris , Roadknight, Gail , Perry, William R , Várnai, Kinga A. , Matharu, Sheila, Starling, Naureen , Teare, Marion, Galdikas, Algirdas, Glampson, Ben , Mercuri, Luca , Wasan, Harpreet , Malcomson, Lee , O’Hara, Catherine M. , Renehan, Andrew G. , Nicholson, Brian D , Davies, Jim , Morris, Eva J.A. , Cunningham, Chris

Mayo Clinic

BMJ Health & Care Informatics | September 22, 2025 | Volume: 32 | Issue: 1 | Pages: e101521

10.1136/bmjhci-2025-101521 | PMID 40983364 Get It

Objectives The ‘tumour, node, metastasis’ (TNM) classification of colorectal cancer (CRC) predicts prognosis and so is vital to consider in analyses of patterns and outcomes of care when using electronic health records. Unfortunately, it is often only available in free-text reports. This study aimed to develop regex-based text-processing algorithms that identify the reports describing CRC and extract the TNM staging at a low computational cost. Methods The CRC and TNM extraction algorithms were iteratively developed using 58 634 imaging and pathology reports of patients with CRC from the Oxford University Hospitals (OUH) and Royal Marsden (RMH) NHS Foundation Trusts (FT), with additional input from Imperial College Healthcare and Christie NHS FTs. The algorithms were evaluated on a stratified random sample of 400 OUH development data reports and 400 newer ‘unseen’ OUH reports. The reports were annotated with the help of two clinicians. Results The CRC algorithm achieved at least 93.0% positive predictive value (PPV), 72.1% sensitivity, 64.0% negative predictive value (NPV) and 90.1% specificity for primary CRC on pathology reports. On imaging reports, it demonstrated at least 78.0% PPV, 91.8% sensitivity, 93.0% NPV and 80.9% specificity. For the main T/N/M categories, the TNM algorithm achieved PPVs of at least 93.9% (T), 97.7% (N) and 97.2% (M), and sensitivities of 63.6% (T), 89.6% (N) and 64.8% (M). NPVs were at least 45.0% (T), 91.1% (N), 88.4% (M), and specificities 95.7% (T), 98.1% (N), 99.3% (M). Reductions in performance were mostly due to implicit staging. For extracting explicit TNM stages, current or historical, the algorithm made no errors on 400 pathology reports and six errors on 400 imaging reports. Conclusion The TNM algorithm accurately extracts explicit TNM staging, but other methods are needed for retrieving implicit stages. The CRC algorithm is accurate on non-supplementary reports, but outputs need additional review if higher precision is required.